Page 2351 - Williams Hematology ( PDFDrive )

2324 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2325

405. Aytekin C, Boyvat F, Kurt A, et al: Catheter-directed thrombolysis with transjugular 437. Avvisati G, Ten Cate JW, Sturke A, et al: Acquired alpha-2-antiplasmin deficiency in
access in portal vein thrombosis secondary to pancreatitis. Eur J Radiol 39:80–82, 2001. acute promyelocytic leukemia. Br J Haematol 70:43–48, 1988.
406. Ciccarelli O, Goffette P, Laterre PF, et al: Transjugular intrahepatic portosystemic shunt 438. Avvisati G, Ten Cate JW, Buller HR, Mandelli F: Tranexamic acid for control of haem-
approach and local thrombolysis for treatment of early posttransplant portal vein orrhage in acute promyelocytic leukemia. Lancet 1989;ii:122–124.
thrombosis. Transplantation 72:159–161, 2001. 439. Rodeghiero F, Avvisati G, Castaman G, et al: Early deaths and anti-hemorrhagic treat-
407. Tateishi A, Mitsui H, Oki T, et al: Extensive mesenteric vein and portal vein thrombo- ments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consec-
sis successfully treated by thrombolysis and anticoagulation. J Gastroenterol Hepatol utive patients. Blood 75:2112–2117, 1990.
16:1429–1433, 2001. 440. Schwartz BS, Williams EC, Conlan MG, Mosher DF: Epsilon-aminocaproic acid in the
408. Calin GA, Calin S, Ionescu R, et al: Successful local fibrinolytic treatment and bal- treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin
loon angioplasty in superior mesenteric arterial embolism: A case report and literature inhibitor deficiency. Ann Intern Med 105:873–877, 1986.
review. Hepatogastroenterology 50:732–734, 2003. 441. Booth NA, Anderson JA, Bennett B: Plasminogen activators in alcoholic cirrhosis:
409. Savassi-Rocha PR, Veloso LF: Treatment of superior mesenteric artery embolism with Demonstration of increased tissue type and urokinase type activator. J Clin Pathol
a fibrinolytic agent: Case report and literature review. Hepatogastroenterology 49:1307– 37:772–777, 1984.
1310, 2002. 442. Hayashi T, Kamogawa A, Ro S, et al: Plasma from patients with cirrhosis increases
410. Haire WD, Atkinson JB, Stephens LC, Kotulak GD: Urokinase versus recombinant tis- tissue plasminogen activator release from vascular endothelial cells in vitro. Liver 18:
sue plasminogen activator in thrombosed central venous catheters: A double-blinded, 186–190, 1998.
randomized trial. Thromb Haemost 72:543–547, 1994. 443. Violi F, Basili V, Ferro D: Association between high values of D-dimer and tissue-
411. Semba CP, Deitcher SR, Li X, et al: Treatment of occluded central venous catheters with plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients.
alteplase: Results in 1,064 patients. J Vasc Interv Radiol 13:1199–1205, 2002. Thromb Haemost 76:177, 1996.
412. Shen V, Li X, Murdock M, et al: Recombinant tissue plasminogen activator (alteplase) 444. Boylan JF, Klinck JR, Sandler AN, et al: Tranexamic acid reduces blood loss, transfusion
for restoration of function to occluded central venous catheters in pediatric patients. requirements, and coagulation factor use in primary orthotopic liver transplantation.
J Pediatr Hematol Oncol 25:38–45, 2003. Anesthesiology 85:1043–1048, 1996.
413. Timoney JP, Malkin MG, Leone DM, et al: Safe and cost effective use of alteplase for the 445. Kaspar M, Ramsay MA, Nguyen AT, et al: Continuous small-dose tranexamic acid
clearance of occluded central venous access devices. J Clin Oncol 20:1918–1922, 2002. reduces fibrinolysis but not transfusion requirements during orthotopic liver transplan-
414. Cooper SG: Original report. Pulse-spray thrombolysis of thrombosed hemodialysis tation. Anesth Analg 85:281–285, 1997.
grafts with tissue plasminogen activator. AJR Am J Roentgenol 180:1063–1066, 2003. 446. Segal HC, Hunt BJ, Cottam S, et al: Fibrinolytic activity during orthotopic liver trans-
415. Cynamon J, Pierpont CE: Thrombolysis for the treatment of thrombosed hemodialysis plantation with and without aprotinin. Transplantation 58:1356–1360, 1994.
access grafts. Rev Cardiovasc Med 3 Suppl 2:84–91, 2002. 447. Soilleux H, Gillon MC, Mirand A, et al: Comparative effects of small and large aprotinin
416. Daeihagh P, Jordan J, Chen J, Rocco M: Efficacy of tissue plasminogen activator admin- doses on bleeding during orthotopic liver transplantation. Anesth Analg 80:349–352,
istration on patency of hemodialysis access catheters. Am J Kidney Dis 36:75–79, 2000. 1995.
417. Hilleman DE, Dunlay RW, Packard KA: Reteplase for dysfunctional hemodialysis cath- 448. Al-Mondhiry H, Manni A, Owen J, Gordon R: Hemostatic effects of hormonal stimu-
eter clearance. Pharmacotherapy 23:137–141, 2003. lation in patients with metastatic prostate cancer. Am J Hematol 28:141–145, 1988.
418. Shrivastava D, Lundin AP, Dosunmu B, et al: Salvage of clotted jugular vein hemodial- 449. Bennett B, Croll AM, Robbie LA, Herriot R: Tumour cell u-PA as a cause of fibrinolytic
ysis catheters. Nephron 68:77–79, 1994. bleeding in metastatic disease. Br J Haematol 99:570–574, 1997.
419. Sobel BE: Intracranial bleeding, fibrinolysis, and anticoagulation. Causal connections 450. Mannucci PM, Cugno M, Bottasso B, et al: Changes in fibrinolysis in patients with
and clinical implications. Circulation 90:2147–2152, 1994. localized tumors. Eur J Cancer 26:83–87, 1990.
420. Sane DC, Califf RM, Topol EJ, et al: Bleeding during thrombolytic therapy for acute 451. Meijer K, Smid WM, Geerards S, van der Meer J: Hyperfibrinogenolysis in dissemi-
myocardial infarction: Mechanisms and management. Ann Intern Med 111:1010–1022, nated adenocarcinoma. Blood Coagul Fibrinolysis 9:279–283, 1998.
1989. 452. Webber MM, Waghray A: Urokinase-mediated extracellular matrix degradation by
421. Alkjaersig N, Fletcher AP, Sherry S: Xi-aminocaproic acid: An inhibitor of plasminogen human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res
activation. J Biol Chem 234:832–837, 1959. 1:755–761, 1995.
422. Andersson L, Nilsson IM, Nilehn JE, et al: Experimental and clinical studies on AMCA, 453. Zacharski LR, Memoli VA, Ornstein DL, et al: Tumor cell procoagulant and urokinase
the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225–1230, 1993.
Scand J Haematol 2:230–247, 1965. 454. Bouchama A, Bridey F, Hammami MM, et al: Activation of coagulation and fibrinolysis
423. Brockway WJ, Castellino FJ: The mechanism of the inhibition of plasmin by in heatstroke. Thromb Haemost 76:909–915, 1996.
xi-aminocaproic acid. J Biol Chem :246:4641–4647, 1971. 455. Harker LA: Bleeding after cardiopulmonary bypass. N Engl J Med 314:1446–1448, 1986.
424. McNicol GP, Fletcher AP, Alkjaersig N, et al: The absorption, distribution and excretion 456. Williams GD, Bratton SL, Nielsen NJ, Ramamoorthy C: Fibrinolysis in pediatric
of xi-aminocaproic acid following oral or intravenous administration to man. J Lab Clin patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 12:633–638,
Med 59:15, 1962. 1998.
425. Huber R, Kukla D, Ruhlmann A, Steigemann W: Pancreatic trypsin inhibitor (Kunitz). 457. Horrow JC, Hlavacek J, Strong MD, et al: Prophylactic tranexamic acid decreases bleed-
I. Structure and function. Cold Spring Harb Symp Quant Biol 36:141–148, 1971, 1972. ing after cardiac operations. J Thorac Cardiovasc Surg 99:70–74, 1990.
426. Ruhlmann A, Kukla D, Schwager P, et al: Structure of the complex formed by bovine 458. Horrow JC, Van Riper DF, Strong MD, et al: Hemostatic effects of tranexamic acid and
trypsin and bovine pancreatic trypsin inhibitor. Crystal structure determination and desmopressin during cardiac surgery. Circulation 84:2063–2070, 1991.
stereochemistry of the contact region. J Mol Biol 77:417–436, 1973. 459. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al: Is epsilon-aminocaproic acid as effective
427. Wiman B: On the reaction of plasmin or plasmin-streptokinase complex with aprotinin as aprotinin in reducing bleeding with cardiac surgery?: A meta-analysis. Circulation
or alpha 2-antiplasmin. Thromb Res 17:143–152, 1980. 99:81–89, 1999.
428. Mangano DT, Tudor IC, Dietzel C: The risk associated with aprotinin in cardiac sur- 460. Soslau G, Horrow J, Brodsky I: Effect of tranexamic acid on platelet ADP during extra-
gery. N Engl J Med 354:353–365, 2006. corporeal circulation. Am J Hematol 38:113–119, 1991.
429. Mouton R, Finch D, Davis I, Zacharowski K: Effect of aprotinin on renal dysfunction. 461. Blomback M, Johansson G, Johnsson H, et al: Surgery in patients with von Willebrand’s
Lancet 372:1543–1544, 2008. disease. Br J Surg 76:398–400, 1989.
430. Schneeweiss S, Seeger JD, Landon J, Walker AM: Aprotinin during coronary-artery 462. Hedlund PO: Antifibrinolytic therapy with Cyklokapron in connection with prostatec-
bypass grafting and risk of death. N Engl J Med 358:771–783, 2008. tomy. A double blind study. Scand J Urol Nephrol 3:177–182, 1969.
431. Shaw AD, Stafford-Smith M, White WD, et al: The effect of aprotinin on outcome after 463. Sindet-Pedersen S, Stenbjerg S: Effect of local antifibrinolytic treatment with tranex-
coronary-artery bypass grafting. N Engl J Med 358:784–793, 2008. amic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 44:703–707,
432. Fergusson DA, Hebert PC, Mazer CD, et al: A comparison of aprotinin and lysine ana- 1986.
logues in high-risk cardiac surgery. N Engl J Med 358:2319–2331, 2008. 464. Callender ST, Warner GT, Cope E: Treatment of menorrhagia with tranexamic acid.
433. Aoki N, Moro M, Matsuda M, Tachiya K: The behavior of alpha-2 plasmin inhibitor in A double-blind trial. Br Med J 4:214–216, 1970.
fibrinolytic states. J Clin Invest 60:361–369, 1977. 465. Ong YL, Hull DR, Mayne EE: Menorrhagia in von Willebrand disease successfully
434. Aoki N, Sakata Y, Matsuda M, Tateno K: Fibrinolytic states in a patient with congenital treated with single daily dose tranexamic acid. Haemophilia 4:63–65, 1998.
deficiency of alpha 1-plasmin inhibitor. Blood 55:483–488, 1980. 466. Ortel TL, Onorato JJ, Bedrosian CL, Kaufman RE: Antifibrinolytic therapy in the man-
435. Dieval J, Nguyen G, Gross S, et al: A lifelong bleeding disorder associated with a defi- agement of the Kasabach Merritt syndrome. Am J Hematol 29:44–48, 1988.
ciency of plasminogen activator inhibitor type 1. Blood 77(3):528–532, 1991. 467. Stahl RL, Henderson JM, Hooks MA, et al: Therapy of the Kasabach-Merritt syndrome
436. Lee MH, Vosburgh E, Anderson K, McDonagh J: Deficiency of plasma plasminogen with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid. Am J Hematol
activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 81:2357–2362, 1993. 36:272–274, 1991.

Kaushansky_chapter 135_p2303-2326.indd 2325 9/18/15 5:14 PM